Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Financing
Filter
Filter
Sort By
Newest First
1 / 24
Modality / Product
Service / Activity
Reset
NIH
The White House’s War on the NIH and the Disasters Ahead
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-25-NI-05
Mar 24, 2025
Leadership Wisdom
Conversations with Carleone: Leadership Wisdom Worth Sharing
Joseph Carleone; Emilee Kudla
Carleone Partners
PAO-03-25-NI-02
Mar 14, 2025
Financing
Ultima Genomics Increases Output by Over 50% and Lowers Sequencing Costs by a Further 20% with the Introduction of UG 100 Solaris™
Ultima Genomics
PR-02-25-NI-26
Feb 25, 2025
Federal Job Cuts
Science Under Siege: The Devastating Consequences of Public Health and Research Cuts
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-25-NI-04
Feb 19, 2025
Financial Result
Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
Cryoport
PR-02-25-NI-13
Feb 18, 2025
Financing
Statement from Aaron J. Kowalski, the Type 1 Diabetes Research and Advocacy Organization, on NIH Indirect Costs Cuts
Breakthrough T1d, Formerly Jdrf
PR-02-25-NI-10
Feb 11, 2025
NIH Funding
NIH Funding Cuts Put Innovation, Health Equity, and Lives at Risk
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-25-NI-03
Feb 10, 2025
Financing
Vetigenics Secures $6 Million Seed Financing, Sees Meaningful Clinical Progress
Vetigenics
PR-01-25-NI-27
Feb 03, 2025
Announcement
NorthX Biologics Appoints Patrick DePalma Senior Vice President of North American Business Development
NorthX Biologics
PR-01-25-NI-22
Jan 20, 2025
Business
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference
Samsung Biologics
PR-01-25-NI-17
Jan 16, 2025
Acquirement
Lilly to Acquire Scorpion Therapeutics' Mutant-Selective PI3Kα Inhibitor Program
Eli Lilly and Company
PR-01-25-NI-14
Jan 14, 2025
Antibody
Timberlyne Therapeutics Secures $180M Series A to Advance CM313, a Promising Anti-CD38 Antibody for High-Need Diseases.
Timberlyne Therapeutics
PR-01-25-NI-07
Jan 10, 2025
Investment
Samsung Invests in Generate: Biomedicines to Advance AI-Driven Protein Therapeutics Discovery
Samsung Biologics
PR-12-24-NI-141
Dec 18, 2024
sustainability
Samsung Biologics Listed Among Top Most Sustainable Companies in Dow Jones Sustainability World Index
Samsung Biologics
PR-12-24-NI-138
Dec 17, 2024
Announcement
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
Theravance Biopharma
PR-12-24-NI-137
Dec 17, 2024
Announcement
Amgen Announces $1 Billion Manufacturing Expansion in North Carolina
Amgen
PR-12-24-NI-129
Dec 06, 2024
Acquisition
Ampersand Capital Partners Aquired Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem
Ampersand Capital Partners
PR-12-24-NI-121
Dec 02, 2024
Financing
EQT Life Sciences leads €54 Million Series A Financing of ATB Therapeutics
EQT
PR-11-24-NI-116
Nov 20, 2024
biotechnology
Atlas Venture targets $450M for 14th biotech fund, the same size as its 2022 raise
Atlas Venture
PR-11-24-NI-111
Nov 18, 2024
Axonics
Boston Scientific Closes Acquisition of Axonics, Inc.
Boston Scientific
PR-11-24-NI-105
Nov 15, 2024
1 / 24
